Breast Cancer, HIV Drugs May Face Tougher Part D Climate Under Protected Class Proposal
Executive Summary
Medicare proposed rule exposes Part D protected class drugs to threat of formulary exclusion if price increases exceed a certain threshold. Here's how it might play out for cancer and HIV drugs.
You may also be interested in...
Part D Protected Class Management Tools To Save Medicare $1.85bn
CMS proposed rule would not eliminate any protected classes but would allow plans to impose additional restrictions on drugs in those classes. Proposal also codifies step therapy for Part B drugs.
Colorado Price Cap Plan For Enbrel Draws Amgen Lawsuit; Cosentyx, Stelara ‘Affordability’ Reviews Pending
However, the state's recently formed prescription drug affordability board found Gilead’s Genvoya and Vertex’s Trikafta to be affordable.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.